Ubrogepant
Evidence-based neurology checklist on ubrogepant: Dose The dose is 50-100mg: it is repeatable after 2 hours Use 50mg if there is renal or hepatic impairment The maximum dose is 200mg in 24 hours It is the least toxic CGRP-RA Indication Contraindications: strong CYP3A4 inhibitors Contraindications:…
Dose
- The dose is 50-100mg: it is repeatable after 2 hours
- Use 50mg if there is renal or hepatic impairment
- The maximum dose is 200mg in 24 hours
- It is the least toxic CGRP-RA
Indication
Contraindications: strong CYP3A4 inhibitors
Contraindications: strong CYP3A4 inducers
Precautions: reduce dose with moderate CYP3A4 inhibitors
Side effects
References
- Scott LJ. Ubrogepant: first approval. Drugs 2020; 80:323-328.
- Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016; 36:887-898.
- Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet 2023; 402:2307-2316.
